ITGAM and neoplasm: Although depletion of CD11b+Ly6G−Ly6C− MDCs and F4/80+ TAMs seemed to have little effect on tumor progression, we determined whether they would have roles in response to therapeutic drugs as frontline chemo-drug treatment or radiation therapies promote myeloid cells [40,41,42,43,44].